Jonathan L. Carter, M.D.

Closed for Enrollment

• A Long-Term Follow-Up Study for Multiple Sclerosis Patients who have Completed the Alemtuzumab Extension Study (CAMMS03409) (TOPAZ) Scottsdale/Phoenix, Ariz.

  The purpose of this study is to evaluate the long-term safety, effectiveness, and patient reported quality of life outcomes of treatment with alemtuzumab for patients who have multiple sclerosis and participated in a previous study of alemtuzumab.

• A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study Comparing the Efficacy and Safety of Ofatumumab versus Teriflunomide in Patients with Relapsing Multiple Sclerosis (ASCLEPIOS I) Scottsdale/Phoenix, Ariz.

  The purpose of this study is to compare the effectiveness and safety of ofatumumab given by injection every 4 weeks, compared to teriflunomide given orally once daily to patients who have relapsing type (returns and worsens unpredictably) multiple sclerosis.

• An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab Scottsdale/Phoenix, Ariz.

  This open-label, rater-blinded extension study will enroll patients who have relapsing-remitting multiple sclerosis (RRMS) and who participated in one of three prior Genzyme-sponsored studies of alemtuzumab [CAMMS223 (NCT00050778), CAMMS323 (NCT00530348) also known as CARE-MS I, or CAMMS324 (NCT00548405) also known as CARE-MS II].

  The purposes of this study are:

  1. To examine the long term safety and efficacy of alemtuzumab treatment in patients who received alemtuzumab as their study treatment in one of the prior studies.

  2. To examine the safety and efficacy of initial alemtuzumab treatment in this study for patients who received Rebif® (interferon beta-1a) as their study treatment in one of the prior studies.

  3. To determine if and when further alemtuzumab treatment is needed, and the safety and efficacy of this "as needed" treatment. This applies both to patients who received alemtuzumab for the first time in one of the prior studies or for the first time in this extension study.

• An Open-Label Phase 1 Study to Evaluate the Safety of ATA188 in Subjects With Progressive and Relapsing-Remitting Multiple Sclerosis Scottsdale/Phoenix, Ariz.

  This is a multicenter, open-label, two-population, single-arm study with a sequential dose-escalation and dose-expansion in adult subjects with progressive forms of multiple sclerosis (MS) and an in adult subjects with relapsed remitting multiple sclerosis (RRMS).

• Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study (SPI2) Scottsdale/Phoenix, Ariz.

  The purpose of this study is to demonstrate the superiority of MD1003 (300 mg/day) over placebo to clinically improve patients with progressive multiple sclerosis (MS).